Details

Autor(en) / Beteiligte

• Shi, Linsen
• Yang, Lin
• Wu, Zhaoyin
• Xu, Wei
• Song, Jun
• Guan, Wenxian

Titel

Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?

Ist Teil von

• International immunopharmacology, 2018-10, Vol.63, p.58-65

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Adenosine (ADO), generated by the ectonucleotidase CD39 and CD73 from ATP, interacts with its specific G protein-coupled receptors, which can impair anti-tumor immune responses inhibiting the infiltration and function of CD8+ T cell and natural killer cell. Recent studies have also identified that ADO pathway plays a critical role in tumor immune surveillance, especially for some non-solid cancers. In addition, although immune checkpoint therapy targeting ADO pathway in gastric cancer is still in an early phase, encouraging results have come out from some drugs targeting ADO pathway. Therefore, target ADO signaling may be a new promising strategy to treat gastric cancer. In this review, we summarized recent works on the role of ADO in cancer immunotherapy and also discussed relative mechanisms underlying the function of ADO signaling in cancer immune responses. •Adenosine can impair anti-tumor immune responses.•Recent studies have also identified that ADO pathway plays a critical role in tumor immune surveillance.•Immune checkpoint therapy targeting ADO pathway in gastric cancer is still in an early phase.•Target ADO signaling may be a new promising strategy to treat gastric cancer.